IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic Melanoma
- Status
- COMPLETED
- Phase
- NA
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia
- Status
- RECRUITING
- Phase
- NA
Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
- Status
- RECRUITING
- Phase
- PHASE2
Lenvatinib and Pembrolizumab With or Without BCAA in Unresectable HCC
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Real-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01)
- Status
- RECRUITING
- Phase
- N/A
Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair Deficiency
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Optimization of Immunotherapy Treatment for Advanced Melanoma in the Context of the Public Brazilian Health System (OTIMAS)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.
- Status
- RECRUITING
- Phase
- PHASE3
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
- Status
- RECRUITING
- Phase
- PHASE3
Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Neoadjuvant Pembrolizumab in Patients With Stage IIb/c Melanoma
- Status
- RECRUITING
- Phase
- PHASE2
Evaluation of UCPVax Vaccine +/- Pembrolizumab Combined With Standard Treatment as Adjuvant Therapy in Patients With Unmethylated MGMT Glioblastoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Study to Identify Biomarkers of Oral Cavity Cancer Response to Neoadjuvant Immunotherapy Prior to Definitive Surgery
- Status
- RECRUITING
- Phase
- NA
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2/PHASE3
A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
- Status
- RECRUITING
- Phase
- PHASE3